Varonis proxy: board asked Thoma Bravo for $54 a share and took $49.75 after eight strategic buyers made no offer
Varonis's preliminary proxy (filed 5 November) for its $6.3B all-cash sale to Thoma Bravo-owned Proofpoint shows Goldman Sachs approached eight strategic buyers from May 2026 and none is described as bidding; the only rival private equity indication, $38-40 a share, was rejected. Proofpoint opened at $36 in May, and Thoma Bravo moved from $43 to $46.50 and $49.50 in August before calling $49.75 its best and final offer, against the board's $54 ask. Break fees settled at 3.375% for Varonis ($211.7M) and 6.75% for Thoma Bravo ($423.3M). CEO Yaki Faitelson's estimated merger-related payments are about $106M; he will stay 18 months and reinvest $15M. There is no headcount commitment for about 2,800 staff, 1,000 of them in Herzliya. Closing is expected in H1 2027.